Josh Mandel-Brehm

President & Chief Executive Officer

Therapeutic Areas

Drug	Indication	Phase
CMP-001	Urea Cycle Disorders	Phase 1/2
CMP-002	SYNGAP1-related disorder	Preclinical
New Discovery Programs	CNS Disorders	Discovery
Collaboration Program	Neurodegenerative & Kidney Diseases	Discovery